449 Search Results Found For : " "

LGM Pharma Appoints CFO

Press Release

ERLANGER, Kentucky / BOCA RATON, Florida – LGM Pharma, an innovation-driven active pharmaceutical ingredient (API) company, headquartered in Erlanger, Kentucky with offices in Florida, New Jersey and Israel recently announced the appointment of Mr. Keith Lavery as chief financial officer (CFO) reporting to Dr. Prasad Raje, the CEO for LGM Pharma. In this capacity, Mr.[…]

Read More

Anidulafungin: An Effective Echinocandin Against Aggressive Fungal Infections

Anti-Fungal

Anidulafungin CAS No: 166663-25-8 Anidulafungin is an antifungal API used to combat general yeast infections found in the blood, stomach, or esophagus and some varieties of Aspergillus. As an echinocandin, it inhibits the growth of fungal cell walls which results in either fungal cell instability or death. Echinocandins are unique in that they affect the[…]

Read More

Tacrolimus – an Effective Immunosuppressant API for a Number of Inflammatory Disorders

Immunosuppressant, OTC and Compounding Product

Tacrolimus CAS No: 104987-11-3 Tacrolimus is an immunosuppressant that has been primarily used to help transplant patients accept their new organs. However, there’s more to this macrolide API than meets the eye. By inhibiting the production of T cells within the body, tacrolimus can be used to help a variety of inflammatory diseases, most notably[…]

Read More

LGM Pharma Announces New CEO

Press Release

ERLANGER, Kentucky / Boca Raton, Florida—LGM Pharma, an innovation-driven active pharmaceutical ingredient (API) company, headquartered in Erlanger, Kentucky with offices in Florida, New York and Israel recently announced that Dr. Prasad S. Raje, Ph.D. would be joining the organization as the company CEO. In that capacity, Dr. Raje will be heading up all company management[…]

Read More

Spotlight on Posaconazole: A Leading Antifungal Medication

Anti-Fungal

Posaconazole CAS No:171228-49-2 Posaconazole is a type of oral triazole antifungal API that has shown a high rate of efficacy for a number of fungal conditions without the risk of severe side effects. While many antifungal medications have ostensibly similar jobs, each one has their own limitations and patient disadvantages. Posaconazole was developed as an[…]

Read More

LGM Pharma Acquires Compounding Business Division From Zeta

LGM Pharma, Press Release

Erlanger, KY / Boca Raton, FL – LGM Pharma LLC today completed the acquisition of Zeta Pharmaceuticals’ compounding business. In Q4 2017, LGM received a significant growth capital investment from private equity firm, New Harbor Capital in Chicago. The acquisition of Zeta’s compounding business is a part of LGM’s strategy to invest in expanding its[…]

Read More

3 of the Newest API’s in the Dermatological Antifungal Segment

Anti-Fungal, EU Approved 2014, FDA Approved 2016

The dermatological antifungal segment has three more FDA approved options. This is good news for a specialty area that could use more diversity when it comes to treating fungal infections. Tavaborole and Efinaconazole were both approved by the FDA in 2014 to treat fungi of the nail and nailbeds, and Crisaborole was approved in 2016[…]

Read More

Lauren Plante Appointed as LGM Pharma’s Newest Business Development Team Member

LGM Pharma, Press Release

LGM Pharma welcomes Lauren Plante as the newest team member of our New York-based business development unit. Lauren will be focused on furthering LGM’s myriad of proactive business initiatives. Her direct responsibilities include CRM functionality and systems integration along with assisting the SVP of Business Development, Steve Beagle, in cultivating strategic relationships with LGM’s clients[…]

Read More

LGM Pharma Exhibits at the 2017 AAPS Annual Meeting and Exposition

LGM Pharma, Trade Shows & Events

The 2017 AAPS Annual Meeting and Exposition took place in San Diego November 12-15. It brought together more than 6,100 scientists, business leaders, government officials, and students from around the world to share and learn the latest scientific advances and industry developments. The meeting featured 100 scientific sessions and 2,200 posters, workshops, and short courses.[…]

Read More

New Harbor Capital Acquires Majority Interest in LGM Pharma

LGM Pharma, Press Release

Chicago-based private equity firm New Harbor Capital completed a majority equity investment in LGM Pharma, an innovation-driven company involved in distribution of cGMP active pharmaceutical ingredients (“API”) and other value-added services supporting leading pharmaceutical companies. LGM specializes in streamlining the API supply chain throughout all development stages while providing complete technical capabilities and expert regulatory[…]

Read More